Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

View Full Paper
Ask AI
Bookmark
Share

Authors

XYXingnong YePrecision for Medicine (United States)CYChunmei YangNortheast Forestry UniversityWXWanzhuo XieZhejiang Cancer Hospital

Discussion

Loading...

Member takes

Overview

Open-label trial demonstrates promising efficacy and safety of orelabrutinib in untreated MZL, indicating potential benefits of BTK inhibitors.

Key Points

  • To assess the efficacy and safety of orelabrutinib plus bendamustine-rituximab or obinutuzumab in untreated marginal zone lymphoma.
  • Multicenter, open-label, single-arm, phase II trial
  • Enrolled treatment-naïve patients with MZL
  • Participants received 3-6 cycles of combination treatment followed by orelabrutinib maintenance
  • Primary endpoint: complete response rate at end of induction treatment
  • Complete response rate of 75% in younger fit patients and 66.7% in older/unfit patients
  • Objective response rate of 93.3% in the overall population
  • Median progression-free survival data remain immature
  • 43.7% experienced grade 3-4 adverse events, primarily hematologic including neutropenia and leukopenia

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da10https://doi.org/10.1182/blood-2025-3596
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.2026
  2. 2Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  3. 3Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  4. 4Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025
  5. 5Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma2026 · 1 citations